A Sequential Triple-Drug Strategy for Selective Targeting of p53-Mutant Cancers.

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• The TP53 tumor suppressor gene (p53) is frequently mutated in human cancers.
• Current treatments for p53 mutant cancers are often ineffective, lack specificity, and cause adverse effects.

Purpose of the Study:

• To develop a novel sequential triple-drug strategy to selectively target p53 mutant cancer cells.

Main Methods:

• Combination therapy with a thymidine analogue (TAS102) and a PARP inhibitor (PARPi) to induce DNA double-strand breaks (DSBs) and G2-arrest in p53 mutant cells.
• Subsequent administration of a G2-checkpoint kinase inhibitor (e.g., WEE1 inhibitor) to trigger mitotic catastrophe in arrested cancer cells.
• Evaluation of drug effects on both p53 mutant cancer cells and normal p53 wild-type cells, including cell cycle progression and DNA repair.

Main Results:

• TAS102-PARPi treatment specifically induced DSBs and G2-arrest in p53 mutant cancer cells, activating DNA repair pathways without inhibiting replication.
• Normal p53 wild-type cells experienced transient G1-arrest and recovered quickly after drug withdrawal.
• Sequential addition of a G2-kinase inhibitor led to massive cell death in p53 mutant cells, while delayed administration minimized toxicity to normal tissues.
• The triple-drug strategy demonstrated significant efficacy in preclinical models of colorectal and pancreatic cancers and was well-tolerated in mice.

Conclusions:

• A sequential triple-drug strategy combining TAS102, PARPi, and a G2-kinase inhibitor offers a promising approach for selectively targeting p53 mutant malignancies.
• This method leverages specific vulnerabilities of p53-deficient cancer cells, leading to effective tumor suppression with reduced toxicity to normal tissues.